Imidazo[1,2-A]Pyridine NMT Inhibitors With Better Cell Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for cytotoxic compounds that are potent inhibitors of human N-myristoyl transferases (NMT) with favorable pharmacokinetic properties such as cell permeability and metabolic stability, suitable for treating hyperproliferative diseases like cancer, as existing inhibitors may not adequately address these requirements.
Innovation Solution
Development of alcohol-substituted imidazo[1,2-a]pyridine compounds that exhibit potent cytotoxic activity and inhibit human NMT, offering improved cell permeability and metabolic stability, suitable for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing NMT inhibitors are used, then NMT inhibition is achieved, but cell permeability and metabolic stability are insufficient
Solution Approach 1:
The patent modifies the chemical structure of NMT inhibitors by introducing specific substituents (R1-R6, R9a-R11, Y, q, s, v parameters) to optimize the balance between NMT inhibition efficacy, cell permeability, and metabolic stability. By systematically varying these structural parameters, the invention achieves compounds that simultaneously satisfy multiple pharmacological requirements that previous inhibitors failed to meet.
2Reliability
If existing NMT inhibitors are used, then NMT inhibition is achieved, but metabolic stability is insufficient
Solution Approach 1:
The patent employs systematic structural modification of the inhibitor molecules by adjusting substituent parameters (R groups, ring structures, linker lengths) to enhance metabolic stability while preserving NMT inhibition activity. This parameter optimization approach allows the invention to achieve compounds with improved pharmacokinetic profiles, including extended metabolic stability, that maintain reliable NMT inhibition.
3Reliability
If potent cytotoxic activity is achieved, then therapeutic effect is improved, but selectivity and safety may be compromised
Solution Approach 1:
The patent introduces specific local structural features (substituents at defined positions R1-R6, heterocyclic rings, linker structures) that enhance cytotoxic activity against hyperproliferative cells while maintaining selectivity. These localized structural modifications allow the inhibitor to preferentially target cancer cells with hyperproliferative characteristics, improving the therapeutic index by differentiating between malignant and normal cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The imidazo[1,2-a]pyridine compounds demonstrate significant cytotoxic activity and NMT inhibition, making them effective for treating or preventing hyperproliferative disorders with enhanced therapeutic potential.
Implementation Method 1
NMT catalyses an irreversible co-translational transfer of myristic acid (a saturated 14-carbon fatty acid) from myristoyl-Coenzyme A (myr-CoA) to a protein substrate containing an N-terminal glycine with formation of an amide bond
Data Source
AI summary
The present invention relates to compounds of formula (I) and related aspects.